author-photo

Ravi K. Anchoori

Johns Hopkins University

26

Papers

638

Citations

Citation Trend

Filter By

Papers (26) Sort By

JournalConferenceOthers

Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.

2021 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (0)
Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties

2020 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (3)
Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-κB signaling.

2020 BMC Cancer
Show All
- Source
- Cite
- Save
Citations (4)
Abstract D051: Targeting ubiquitin receptor ADRM1 for the treatment of quadruple-negative breast cancer

2020 Cancer Epidemiology, Biomarkers & Prevention
Show All
- Source
- Cite
- Save
Citations (0)
mTORC1 feedback to AKT modulates lysosomal biogenesis through MiT/TFE regulation

2019 Journal of Clinical Investigation
Show All
- Source
- Cite
- Save
Citations (5)
Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer

2018
Show All
- Source
- Cite
- Save
Citations (15)
Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma

2017 Journal of Ovarian Research
Show All
- Source
- Cite
- Save
Citations (9)
Abstract A74: Proteasome subunit RPN13 as a candidate target for treatment of ovarian carcinoma.

2016 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells

2016 Oncotarget
Show All
- Source
- Cite
- Save
Citations (19)
The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression.

2016 Journal of Biological Chemistry
Show All
- Source
- Cite
- Save
Citations (41)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号